Pharmaceutical manufacturing revenue continued to pick up, pharmaceutical equipment industry ushered in a good opportunity for development.

Pharmaceutical Network Market Analysis: Pharmaceutical manufacturing industry refers to the chemical pharmaceutical industry (including chemical raw materials and chemical agents), Chinese medicine industry (including traditional Chinese medicine manufacturing and Chinese medicine tablet processing), biopharmaceutical industry and medical equipment and equipment manufacturing sub-industry.
since the first half of this year, although the pharmaceutical manufacturing industry has been affected by the special period, total profits have continued to grow compared with the same period a year earlier, and overall industry revenue has continued to pick up.
in this context, the industry believes that the pharmaceutical equipment industry also ushered in a good opportunity for development.
Pharmaceutical Equipment (Source: Pharmaceutical Network) Pharmaceutical manufacturing revenue continued to pick up data released by the National Bureau of Statistics, the pharmaceutical manufacturing industry in January-June 2020, while revenue decreased by 2.3% year-on-year, the total profit increased by 0.8% year-on-year.
can see that the pharmaceutical industry as a whole continued to pick up in June.
the second half of the year, with the continuous deepening of consistency evaluation, the implementation of the third batch of national collection, and the development of a new round of adjustment work in the medical insurance catalog, the industry believes that the pharmaceutical manufacturing industry revenue and profit growth will still face certain pressure, the differentiation of competitiveness of enterprises intensified.
Because the pharmaceutical manufacturing industry is technology-intensive and capital-intensive industries, the research and development capabilities, cost control capabilities, variety reserves, capital strength of pharmaceutical manufacturing enterprises will be considered.
and in the long run, because drugs are related to the national economy and people's livelihood, with the aging of the population, cardiovascular, diabetes and other chronic diseases will increase the proportion of disease, as well as the level of consumption is constantly upgrading, the adjustment of drug demand structure will accelerate, the pharmaceutical manufacturing industry will continue to develop towards standardization and scientific development.
pharmaceutical equipment industry ushered in a good opportunity for development from the pharmaceutical manufacturing industry chain, pharmaceutical equipment manufacturing industry also has demand rigidity.
" the overall profitability of the pharmaceutical manufacturing industry is still at a high level, the pharmaceutical equipment industry will usher in the development of the opportunity, how to balance innovation and cost, quality and price of the relationship between the pharmaceutical equipment enterprises are the key to success or failure.
" is said by the industry.
in terms of innovation and cost, innovation has become the main theme of the development of the pharmaceutical industry, and its close relationship with the pharmaceutical equipment industry in order to meet the needs of pharmaceutical companies, but also need to keep pace with the times, continuous innovation and upgrading.
but innovation can not be separated from research and development investment and talent investment, in the current pharmaceutical equipment industry labor costs continue to rise, raw material prices in the background, how to balance innovation and cost is a major challenge.
to this, there are drug machine people pointed out that the current domestic pharmaceutical machine enterprises in production management, management and other aspects of the existence of obvious short board, need to "lean management" direction of upgrading.
the author learned that the current lean management has become a number of domestic pharmaceutical enterprise development of an important strategic direction, and obtain some results.
for example, Dongfulong recently disclosed the first half of 2020 results forecast shows that the company's first-half net profit increased by 330% to 360%, profit of 164 million yuan to 176 million yuan.
for the reasons for the pre-growth performance, the company said, on the one hand, actively explore the market, pharmaceutical equipment sector and medical technology sector revenue increased year-on-year;
in terms of quality and price, the current domestic pharmaceutical equipment import substitution speed is accelerating, basically can meet the production needs of domestic pharmaceutical manufacturers, but for example, centrifuges and other equipment is still mainly concentrated in the low-end market, high-end still dominated by imported equipment.
has been, domestic pharmaceutical equipment in the market competition to low-tech, low-price competition as a means, with the rapid development of the domestic pharmaceutical equipment industry, market competition is becoming more intense, how to change from low-cost competition to high-quality competition to achieve the domestic pharmaceutical machine industry "transformation" of major challenges.
", "Now the market product overlap rate has been very high, continue the price war equals a dead end, should return to technology and quality.
" has the drug machine people pointed out, especially in this regard of the core technology, domestic pharmaceutical machine enterprises need to constantly strengthen technological innovation, complement the core technology short board.
also need to keep up with the "smart manufacturing" trend, grasp the development direction of high-precision, to create more really in line with the new needs and requirements of pharmaceutical companies high-quality products.
.